Skin Cancer, Acne, Skin Injury | Dermatology News, Treatment …
While HIPAA rules protect health information of patients in hospitals and for physician visits, generally they do not protect the privacy or security of a patient’s health and wellness information when it is created accessed through or stored on personal cell …
FDA Alerts in Dermatology (Updated December 2024)
1 day ago · The United States Food and Drug Administration reported changes in drug approvals, warnings, and indications for products for dermatologic use in 2024. Throughout 2024, the Food and Drug Administration (FDA) approved various new drugs and products, granted new indications for already approved drugs ...
FDA Expands Approval of Vtama to Include Atopic Dermatitis
1 day ago · The nonsteroidal topical treatment is approved for patients 2 years and older. HealthDay News — The U.S. Food and Drug Administration has approved Vtama (tapinarof) 1 percent cream for an additional indication — the topical treatment of atopic dermatitis in adult and pediatric patients aged 2 ...
FDA Approves Nemluvio for Moderate to Severe Atopic Dermatitis
5 days ago · The approval is for use in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies. HealthDay News — The U.S. Food and Drug Administration has approved Nemluvio (nemolizumab) for the ...
AAD Issues New Guidelines for Clinical Management of Acne …
Mar 22, 2024 · The American Academy of Dermatology (AAD) has issued updated guidelines for the clinical management of patients with acne vulgaris, which have been published in the Journal of the American Academy of Dermatology.. Systematic reviews to evaluate the effectiveness and safety of acne treatments approved by the United States Food and Drug Administration (FDA) were performed from May 2021 to ...
Treatment of Moderate to Severe Atopic Dermatitis: Highlights …
From March 17 to 21, 2023, dermatologists gathered for the American Academy of Dermatology (AAD) Annual Meeting, where they discussed the latest research on the treatment and management of a range of inflammatory skin diseases and other conditions. In this article, Emma Guttman-Yassky, MD, PhD, discusses the most exciting research on the treatment of moderate to severe atopic dermatitis ...
Long-Term Dupilumab Is Safe, Effective for Atopic Dermatitis for …
Aug 23, 2024 · Included in the safety analysis were 2677 patients, of whom 60.2% were men. Mean (SD) patient age was 39.2 (13.4) years. The majority (82.4%) of patients continued treatment with dupilumab for at least 52 weeks and 12.5% continued treatment up to week 260 (5 years). Approximately half (48.4%) of patients completed both treatment and an end-of-study visit.
Systemic Treatments for Atopic Dermatitis: Which is Most Effective?
Sep 10, 2024 · Dupilumab was more effective when compared with methotrexate (MTX) for the treatment of patients with atopic dermatitis (AD), and cyclosporin (CyA) was most effective in those with very severe disease, according to study findings published in the British Journal of Dermatology.. Researchers conducted a prospective observational cohort study to compare the real-world clinical effectiveness and ...
Atopic Dermatitis Has High Global Burden - Dermatology Advisor
Oct 4, 2024 · The estimated global point prevalence of atopic dermatitis (AD) is 11.1% for children and adolescents and 6.3% for adults, with significant variability observed in the proportion of severe disease among these patients.
Atopic Dermatitis Treatment Access Often Hampered by Insurance …
Jul 25, 2024 · Nearly 50% of patients with atopic dermatitis (AD) in the United States reported an insurance-related delay or denial for obtaining recommended treatment within the previous year, according to study results published in Dermatology and Therapy.. In a cross-sectional, observational study, a team of investigators from the National Eczema Association (NEA), Novato, CA and the Center for Medical ...